Detection, localisation and characterisation of prostate cancer by prostate HistoScanning™

BJU International

Volumn 110, Issue 1, 2012, Pages 28-35

  Simmons, Lucy A M ^a   Autier, Philippe ^c   Zát'ura, Frantiŝek ^d   Braeckman, Johan ^e   Peltier, Alexandre ^f   Romic, Imre ^h   Stenzl, Arnulf ⁱ   Treurnicht, Karien ^b   Walker, Tara ^b   Nir, Dror ^g   Moore, Caroline M ^a   Emberton, Mark ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BOSTWICK LABORATORIES   (United States)

^c INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^d UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^f JULES BORDET INSTITUTE   (Belgium)

^g Advanced Medical Diagnostics SA   (Belgium)

^h Semmelweis Hospital   (Hungary)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Detection; Diagnosis; HistoScanning ; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MULTICENTER STUDY; OPEN STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TUMOR VOLUME; ULTRASOUND SCANNER;

AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 84862286426     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10734.x     Document Type: Article

References (21)

1. Al Otaibi M, Ross P, Fahmy N et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 2008; 113: 286-92
2. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202
3. Serkin FB, Soderdahl DW, Cullen J, Chen Y, Hernandez J. Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7. Urol Oncol 2010; 28: 302-7
4. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 1997; 157: 559-62 (Pubitemid 27026838)
5. King CR, McNeal JE, Gill H, Presti JC Jr. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys 2004; 59: 386-91 (Pubitemid 38622590)
6. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007; 52: 1309-22 (Pubitemid 47446019)
7. Onik G, Barzell W. Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 2008; 26: 506-10
8. Zietman A. Evidence-based medicine, conscience-based medicine, and the management of low-risk prostate cancer. J Clin Oncol 2009; 27: 4935-6
9. Braeckman J, Autier P, Garbar C et al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int 2008; 101: 293-8
10. Braeckman J, Autier P, Soviany C et al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int 2008; 102: 1560-5
11. Advanced Medical Diagnostics, Belgium. Prostate HistoScanning for the non-invasive detection and staging of prostate cancer and characterization of prostate tissues (PHS-02). 2010. Available at: http://clinicaltrials.gov/ct2/ show/NCT01191931?term=nct01191931&rank=1. Accessed January 2011
12. Bossuyt PM, Reitsma JB, Bruns DE et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138: W1-12
13. The Royal College of Radiologists, London. Ultrasound training recommendations for medical and surgical specialties. 2005 ISBN 1-1-2005. 2-6-2011. Ref Type: Online Source Available at: http://www.rcr.ac.uk/docs/ radiology/pdf/ultrasound.pdf. Accessed April 2011
14. Ahmed HU, Kirkham A, Arya M et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009; 6: 197-206
15. Xu S, Kruecker J, Turkbey B et al. Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg 2008; 13: 255-64
16. Klotz L. Active surveillance for prostate cancer: patient selection and management. Curr Oncol 2010; 17 (Suppl. 2): S11-7
17. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006; 176: 2432-7 (Pubitemid 44665992)
18. Delongchamps NB, Rouanne M, Flam T et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int 2011; 107: 1411-8
19. Lacy GL 2nd, Soderdahl DW, Hernandez J. Optimal cost-effective staging evaluations in prostate cancer. Curr Urol Rep 2007; 8: 190-6 (Pubitemid 46806647)
20. Seitz M, Gratzke C, Schlenker B et al. Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol 2011; 29: 295-301
21. Trabulsi EJ, Sackett D, Gomella LG, Halpern EJ. Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer. Urology 2010; 76: 1025-33